Abstract Meningiomas, accounting for the bulk of primary intracranial neoplasms and exhibiting a striking female bias, harbor potential hormonal dependencies. This investigation delineates estrogen receptor (ER) and progesterone receptor (PR) profiles via immunohistochemistry (IHC), correlating them with salient clinicopathological attributes. This ambispective, observational analysis encompassed 100 histologically verified meningioma specimens accrued from September 2017 to August 2022. Specimens with depleted tissue or absent consent were excluded; IHC was executed on 50 cases using adequate FFPE tissue blocks as available. The peak incidence occurred in the 41 to 50-year age group (30%), with a female-to-male ratio of 1.85:1. Convexity emerged as the most prevalent site (50%), the transitional subtype was the most common (36%), and WHO Grade I was the most dominant. ER positivity manifested in 12%, principally among fifth-decade patients (33.3%), females (83.3%), transitional variants (66.7%), and solely Grade I lesions. PR positivity prevailed in 58% of cases, notably in the fifth decade (31%), females (62.1%), convexity tumors (41.4%), transitional histology (48.3%), and Grade I neoplasms (89.7%), with 28.6% brain invasion, 3.4% bone invasion, and 3.4% recurrence. Meningiomas burgeon in middle-aged females, predominantly as WHO Grade I entities. PR is more frequently expressed in lower-grade tumors but no significant associations were found and prognostic significance could not be determined.
Palmal et al. (Tue,) studied this question.